Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol

Basit Öğe Kaydı
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorÜmit, Elif Gülsüm
dc.contributor.authorSarıtaş, Fatih
dc.contributor.authorKodal, Nil Su
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2021-11-20T10:10:04Z
dc.date.available2021-11-20T10:10:04Z
dc.date.issued2018
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.description.abstractBackground: Certolizumab pegol is used to treat ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis. Unlike other monoclonal antibodies such as infliximab and adalimumab, certolizumab does not contain an Fc fraction and hence does not induce complement activation. In this report, we describe the case of a patient with thrombotic microangiopathy caused due to certolizumab pegol, with a brief description about the pathophysiological approach to thrombotic microangiopathy. Case Report: A-39-year-old man suffering from ankylosing spondylitis for the past 10 years presented with fatigue. He had been on certolizumab pegol treatment for 6 months, starting with 400 and 200 mg every 2 weeks. He had significant nonimmune hemolytic anemia and thrombocytopenia without a disseminated intravascular coagulopathy. Schistocytes were observed in more than 10% of the erythrocytes per field. Plasma exchange along with corticosteroid treatment was started. There was a dramatic improvement within a week, and after 10 sessions of plasma exchange, the patient was discharged on corticosteroids with a tapering plan. ADAMTS13 enzyme activity was determined to be normal. Conclusion: The development of drug-induced thrombotic microangiopathy may be either immune-mediated or dose-dependent toxicity-mediated Anti-drug antibodies and their immunological aspects are still unclear and yet to be elucidated.en_US
dc.identifier.doi10.4274/balkanmedj.2017.1224en_US
dc.identifier.endpage399en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue5en_US
dc.identifier.pmid29687787en_US
dc.identifier.scopus2-s2.0-85054080940en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage398en_US
dc.identifier.trdizinid289905en_US
dc.identifier.urihttps://doi.org/10.4274/balkanmedj.2017.1224
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpnNU9UQTFOUT09
dc.identifier.urihttps://hdl.handle.net/20.500.14551/5499
dc.identifier.volume35en_US
dc.identifier.wosWOS:000445256500009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectGenel ve Dahili Tıpen_US
dc.titleDrug Induced Thrombotic Microangiopathy with Certolizumab Pegolen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5499.pdf
Boyut:
303.23 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Balkan Medical Journal
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu